AstraZeneca Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2000
Net Income	5,955	3,288	112	3,196	1,335	Upgrade
Depreciation & Amortization	5,387	5,480	6,530	3,149	3,762	Upgrade
Other Operating Activities	-997	1,040	-679	-1,546	-2,128	Upgrade
Operating Cash Flow	10,345	9,808	5,963	4,799	2,969	Upgrade
Operating Cash Flow Growth	5.48%	64.48%	24.26%	61.64%	13.41%	Upgrade
Capital Expenditures	-1,229	-809	-1,078	96	-942	Upgrade
Acquisitions	-989	-1,061	-9,413	-790	-633	Upgrade
Change in Investments	97	-114	96	745	194	Upgrade
Other Investing Activities	-1,943	-976	-663	-336	724	Upgrade
Investing Cash Flow	-4,064	-2,960	-11,058	-285	-657	Upgrade
Dividends Paid	-4,481	-4,364	-3,856	-3,572	-3,592	Upgrade
Share Issuance / Repurchase	33	29	29	30	3,525	Upgrade
Debt Issued / Paid	-2,100	-2,361	7,654	1,440	-1,702	Upgrade
Other Financing Activities	-19	-127	-178	-101	4	Upgrade
Financing Cash Flow	-6,567	-6,823	3,649	-2,203	-1,765	Upgrade
Exchange Rate Effect	-60	-80	-62	12	5	Upgrade
Net Cash Flow	-286	25	-1,446	2,311	547	Upgrade
Free Cash Flow	9,116	8,999	4,885	4,895	2,027	Upgrade
Free Cash Flow Growth	1.30%	84.22%	-0.20%	141.49%	27.73%	Upgrade
Free Cash Flow Margin	19.90%	20.29%	13.06%	18.39%	8.31%	Upgrade
Free Cash Flow Per Share	2.94	2.91	1.72	1.86	0.78	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).